Pulsenmore (TASE: PULS), a provider of home-based ultrasound technology, announced on Wednesday that it has renewed and expanded its partnership with Clalit Health Services, Israel's largest HMO. Over the next five years, Pulsenmore will supply 25,000 advanced home ultrasound devices, enhancing Clalit's commitment to accessible prenatal care.
The Pulsenmore platform allows expectant mothers to conduct ultrasound scans from home, improving access to healthcare. Under the new agreement, devices will enable both asynchronous (App Guided) and synchronous (Clinician Guided) scans through real-time video consultations, empowering women with direct access to quality prenatal care.
Clalit will also explore integrating Pulsenmore's latest home-based Biophysical Profile (BPP) feature, which assists medical teams in assessing fetal well-being and making timely decisions for high-risk pregnancies. The home ultrasound device, connected via smartphone, allows users to perform self-guided scans, with data securely sent to medical professionals for remote evaluation. This intuitive technology captures vital fetal health metrics, including heartbeat, movement, and amniotic fluid levels.
Founded in 2014, Pulsenmore has achieved rapid growth, obtaining regulatory approvals in Israel and Europe, and recently gaining clearance for distribution in Australia and Brazil. The company reported a robust 79% revenue growth in the first half of the year and anticipates committed contractual revenue through 2025, positioning itself as a transformative force in prenatal care.
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
PharmaNutra signs agreement with strategic consulting firm for US development plan
BD launches advanced Intraosseous Vascular Access System for rapid emergency use
Pulsenmore to supply 25,000 home ultrasound devices to Clalit Health Services
Medtronic announces new, long-term data from SPYRAL HTN-ON MED clinical trial
Senzime unveils next-gen TetraGraph TOF monitor at ANESTHESIOLOGY 2024; US shipments to begin in Q4
Abbott launches new clinical trial to improve results in patients with advanced heart failure
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Adocia patents stable hormone combinations for obesity and diabetes